Skip to main content

Advertisement

SpringerLink
Log in

Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

This study was designed to evaluate the tolerability and therapeutic activity of paclitaxel and carboplatin combination therapy followed by radical thoracic radiotherapy with a concomitant boost technique with concurrent weekly paclitaxel in good performance status of patients with stage IIIA and IIIB non-small cell lung cancer. Patients with newly diagnosed inoperable non-small cell lung cancer received paclitaxel (100 mg/m2) as a 1-h infusion on d 1,8,15,28,35, and 42. Carboplatin (area under the curve of 6) was given as a 30-min infusion on d 1 and 28. Radiotherapy commenced on d 49 and was delivered with accelerated fractionation with concomitant boost at 1.8 Gy/fraction/d, 5 d/week and 1.5 Gy/fraction/d to a boost field as a second daily treatment for the last 10 treatment days to 60 Gy/35 fractions/5 wk. During radiation treatment, paclitaxel (60 mg/m2) was given as a 1-h infusion once weekly for 5 wk. Twenty-four patients were enrolled in the study. Hematologic toxicities and alopecia were the major acute toxicities during induction chemotherapy; 8.7% of the patients experienced grade 3–4 neutropenia and alopecia. The main acute toxicity of concurrent chemoradiotherapy was esophagitis; grade 3 esophagitis was documented in 23.5% of the patients. No major late toxicity was seen. Overall response rate to the treatment was 65.2%. The median and 1-yr overall-survival rates were 24.9 mo and 63.8%, respectively. The median and 1-yr progression-free survival rates were 9.0 mo and 27.8%, respectively. The main acute toxicities were hematologic toxicity, esophagitis, and alopecia. The response rate and the survival rates achieved with this treatment regimen are particularly noteworthy, especially considering the advanced stage of the patients treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wagner H. Radiation therapy in the management of patients with unresectable stage III A patients and III B non-small cell lung cancer. Semin Oncol 1997;24:423–428.

    PubMed  Google Scholar 

  2. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol 2000;10(4):289–295.

    Article  PubMed  CAS  Google Scholar 

  3. Saunders M, et al. Continuous, hyperfactionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Comittee. Radiother Oncol 1999;52:137–148.

    Article  PubMed  CAS  Google Scholar 

  4. Cox J.D, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543–1555.

    PubMed  CAS  Google Scholar 

  5. Arriagada R, et al. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small-cell lung cancer (NSCLC): late analysis of a French randomized trial. Proc Am Soc Clin Oncol 1997;16:446a.

    Google Scholar 

  6. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 84-33 trial. J Natl Cancer Inst 1996;88:1210–1215.

    Article  PubMed  CAS  Google Scholar 

  7. Sause WT, et al. Final results of phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358–364.

    Article  PubMed  CAS  Google Scholar 

  8. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065–1070.

    PubMed  CAS  Google Scholar 

  9. Furuse K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692–2699.

    PubMed  CAS  Google Scholar 

  10. Curran W, et al. Long term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc AM Soc Clin Oncol 2003;22:721a.

    Google Scholar 

  11. Mornex F, et al. Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): a French randomized phase III trial of GLOT-GFPC (NPC 95-01 study). Eur J Cancer 2001;37(Suppl 6):28.

    Article  Google Scholar 

  12. Zatloukal P, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87–98.

    Article  PubMed  Google Scholar 

  13. Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol 2001;13:110–115.

    Article  PubMed  CAS  Google Scholar 

  14. Saunders MI. Programming of radiotherapy in the treatment of non-small cell lung cancer-a way to advance care. Lancet Oncol 2001;2:401–408.

    Article  PubMed  CAS  Google Scholar 

  15. Mattson K, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477–482.

    Article  PubMed  CAS  Google Scholar 

  16. Morton RF, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non- small-cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991;115:681–686.

    PubMed  CAS  Google Scholar 

  17. Akerley W, et al. Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 2000;19:1915a.

    Google Scholar 

  18. Socinski M, et al. Induction (I) and concurrent (C) carboplatin/paclitaxel (C/P) with dose-escalated thoracic conformal radiotherapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC): a phase I/II trial. Proc Am Soc Clin Oncol 2000;19:1940a.

    Google Scholar 

  19. Nuria V, et al. Radiotherapy (RT) with concurrent paclitaxel plus carboplatin and paclitaxel administered as induction and consolidation chemotherapy (CT) in locally advanced non small cell lung cancer (NSCLC). Phase II trial. Lung Cancer 2003;41:S242.

    Google Scholar 

  20. Leong SS, et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer—long-term results of a prospective study. Respiratory Medicine 2004;98:1080–1086.

    Article  PubMed  Google Scholar 

  21. Cox JD. Induction chemoterapy for non small cell carcinoma of the lung: limitations and lessons. Int J Radiat Oncol Biol Phys 1991;20:1375–1376.

    PubMed  CAS  Google Scholar 

  22. Trott KR, Kummermehr K. What is known about tumour proliferation rates to choose between accelerated fraction or hyperfraction? Radioter Oncol 1984;3:1–10.

    Article  Google Scholar 

  23. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131–146.

    PubMed  CAS  Google Scholar 

  24. Schuster-Uitterhoeve ALJ, Hulshof MCCM, Gonzales DG, Koolen M, Sminia P. Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with nonsmall cell lung cancer (NSCLC). Radiother Oncol 1993;28:247–251.

    Article  PubMed  CAS  Google Scholar 

  25. Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 1995;31:819–825.

    Article  PubMed  CAS  Google Scholar 

  26. King SC, et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. Int J Radiat Oncol Biol Phys 1996;36:593–599.

    Article  PubMed  CAS  Google Scholar 

  27. Sun LM, et al. Concomitant boost radiation therapy for inoperable non-small cell lung cancer: Preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 2000;47:413–418.

    Article  PubMed  CAS  Google Scholar 

  28. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22:570–574.

    Google Scholar 

  29. Choy H, Safran H. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995;22:555–557.

    Google Scholar 

  30. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–1346.

    Article  PubMed  CAS  Google Scholar 

  31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.

    Article  Google Scholar 

  32. Cox JD, et al. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991;20:7–12.

    PubMed  CAS  Google Scholar 

  33. Komaki R, et al. Induction cisplatin/vinblastine and irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997;39:537–544.

    Article  PubMed  CAS  Google Scholar 

  34. Schaake-Koning C, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Eng J Med 1992;326:524–530.

    Article  CAS  Google Scholar 

  35. Penland SK, Socinski MA. Management of unresectable stage III non-small-cell lung cancer. The role of combined chemoradiation. Semin Radiat Oncol 2004;14:326–334.

    Article  PubMed  Google Scholar 

  36. Cox JD, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543–1555.

    PubMed  CAS  Google Scholar 

  37. Saunders MI, et al. Experience with dose escalating using CHARTWEL (continuous, hyperfractionated, accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998;78:1323–1328.

    PubMed  CAS  Google Scholar 

  38. Fu KK, et al. A Radiation Therapy Oncology Group (RTOG) phase III radnomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7–16.

    Article  PubMed  CAS  Google Scholar 

  39. Lau DH, et al. Twice weekly paclitaxel and radiation for stage III non-small-cell lung cancer. Semin Oncol 1997;24(Suppl 12):S12-106–S12-109.

    Google Scholar 

  40. Oral EN, et al. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 1999;25:191–198.

    Article  PubMed  CAS  Google Scholar 

  41. Havemann K, et al. Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small-cell lung cancer. Semin Oncol 1995;22(Suppl 14):19–22.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instute of Oncology, Istanbul University, 34390, Capa, Istanbul, Turkey

    Ethem Nezih Oral, Adnan Aydiner, Yeşim Eralp & Erkan Topuz

Authors
  1. Ethem Nezih Oral
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adnan Aydiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeşim Eralp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ethem Nezih Oral.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oral, E.N., Aydiner, A., Eralp, Y. et al. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer. Med Oncol 22, 367–374 (2005). https://doi.org/10.1385/MO:22:4:367

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:4:367

Key Words

Search

Navigation